<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6318">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01031004</url>
  </required_header>
  <id_info>
    <org_study_id>CR-1655</org_study_id>
    <nct_id>NCT01031004</nct_id>
  </id_info>
  <brief_title>Vistakon Investigational Lens Worn as a Single Use Daily Wear</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to show that the investigational contact lens is clinically
      equivalent to a currently approved contact lens, when worn as single-use on a daily basis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Slit Lamp Findings - Corneal Edema</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Investigators examined subjects using a slit lamp and the following scale: 0=none, 1=trace, 2=mild, 3=moderate, 4=severe. This outcome measures the number of eyes that had corneal edema graded 2 or higher at the 1-week visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Edema at Month 1</measure>
    <time_frame>after 1 month of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of eyes with corneal edema graded 2 or higher at the 1 month visit. Investigators examined subjects using a slit lamp and the following scale: 0=none, 1=trace, 2=mild, 3=moderate, 4=severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit Lamp Findings - Corneal Neovascularization</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had corneal neovascularization graded 2 or higher at the 1-week visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit Lamp Findings - Corneal Neovascularization</measure>
    <time_frame>after 1 month of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had corneal neovascularization graded 2 or higher at the 1-week visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit Lamp Findings - Corneal Staining</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had corneal staining graded 2 or higher at the 1-week visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit Lamp Findings - Corneal Staining</measure>
    <time_frame>after 1 month of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had corneal staining graded 2 or higher at the 1-week visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit Lamp Findings - Injection</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had injection graded 2 or higher at the 1-week visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit Lamp Findings - Injection</measure>
    <time_frame>after 1 month of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had injection graded 2 or higher at the 1-week visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit Lamp Findings - Tarsal Abnormalities</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had tarsal abnormalities graded 2 or higher at the 1-week visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit Lamp Findings - Tarsal Abnormalities</measure>
    <time_frame>after 1 month of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had tarsal abnormalities graded 2 or higher at the 1-week visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit Lamp Findings - Infiltrates</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Investigators examined subjects using a slit lamp and recorded the presence or absence of infiltrates. This outcome measures the number of eyes that had infiltrates present at the 1-week visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit Lamp Findings - Infiltrates</measure>
    <time_frame>after 1 month of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Investigators examined subjects using a slit lamp and recorded the presence or absence of infiltrates. This outcome measures the number of eyes that had infiltrates present at the 1-week visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject Reported Symptoms</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of eyes in which subjects reported lens-related symptoms after 1 week of lens wear.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject Reported Symptoms</measure>
    <time_frame>after 1 month of lens wear</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of eyes in which subjects reported lens-related symptoms after 1 month of lens wear.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity (VA)</measure>
    <time_frame>after 1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigators assessed visual acuity per eye using a Snellen visual acuity chart. This outcome measures the number of eyes, wearing vision correction, that measured visual acuity worse than 20/30 at the 1-week visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity (VA)</measure>
    <time_frame>after 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigators assessed visual acuity per eye using a Snellen visual acuity chart. This outcome measures the number of eyes, wearing vision correction, that measured visual acuity worse than 20/30 at the 1-month visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Wear Time</measure>
    <time_frame>after 1 week of lens wear</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Wear Time</measure>
    <time_frame>after 1 month of lens wear</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>narafilcon B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>contact lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>narafilcon B</intervention_name>
    <description>contact lens</description>
    <arm_group_label>narafilcon B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A</intervention_name>
    <description>contact lens</description>
    <arm_group_label>etafilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  eyes must be best-corrected to a visual acuity of 20/30 or better in each eye

          -  must be able and willing to wear soft contact lenses on a single use, daily wear
             basis for the duration of the study

          -  distance spherical contact lens prescription must be within the range available for
             the study

        Exclusion Criteria:

          -  systemic diseases which may interfere with contact lens wear

          -  ocular infection or clinically significant ocular disease

          -  any previous intraocular surgery

          -  grade 2 or greater slit lamp findings

          -  currently pregnant or lactating

          -  more than 1.00D of refractive astigmatism in either eye
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larimie</city>
        <state>Wyoming</state>
        <zip>82070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 6, 2015</lastchanged_date>
  <firstreceived_date>November 18, 2009</firstreceived_date>
  <firstreceived_results_date>February 22, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Narafilcon B</title>
          <description>single use, daily wear contact lens</description>
        </group>
        <group group_id="P2">
          <title>Etafilcon A</title>
          <description>contact lens worn as single use, daily wear</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Narafilcon B</title>
          <description>single use, daily wear contact lens</description>
        </group>
        <group group_id="B2">
          <title>Etafilcon A</title>
          <description>contact lens worn as single use, daily wear</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.2" spread="8.19"/>
                <measurement group_id="B2" value="29.2" spread="8.08"/>
                <measurement group_id="B3" value="29.2" spread="8.13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings - Corneal Edema</title>
        <description>Investigators examined subjects using a slit lamp and the following scale: 0=none, 1=trace, 2=mild, 3=moderate, 4=severe. This outcome measures the number of eyes that had corneal edema graded 2 or higher at the 1-week visit.</description>
        <time_frame>after 1 week of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Slit Lamp Findings - Corneal Edema</title>
            <description>Investigators examined subjects using a slit lamp and the following scale: 0=none, 1=trace, 2=mild, 3=moderate, 4=severe. This outcome measures the number of eyes that had corneal edema graded 2 or higher at the 1-week visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Edema at Month 1</title>
        <description>Number of eyes with corneal edema graded 2 or higher at the 1 month visit. Investigators examined subjects using a slit lamp and the following scale: 0=none, 1=trace, 2=mild, 3=moderate, 4=severe.</description>
        <time_frame>after 1 month of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Corneal Edema at Month 1</title>
            <description>Number of eyes with corneal edema graded 2 or higher at the 1 month visit. Investigators examined subjects using a slit lamp and the following scale: 0=none, 1=trace, 2=mild, 3=moderate, 4=severe.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings - Corneal Neovascularization</title>
        <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had corneal neovascularization graded 2 or higher at the 1-week visit.</description>
        <time_frame>after 1 week of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Slit Lamp Findings - Corneal Neovascularization</title>
            <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had corneal neovascularization graded 2 or higher at the 1-week visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings - Corneal Neovascularization</title>
        <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had corneal neovascularization graded 2 or higher at the 1-week visit.</description>
        <time_frame>after 1 month of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Slit Lamp Findings - Corneal Neovascularization</title>
            <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had corneal neovascularization graded 2 or higher at the 1-week visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings - Corneal Staining</title>
        <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had corneal staining graded 2 or higher at the 1-week visit.</description>
        <time_frame>after 1 week of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Slit Lamp Findings - Corneal Staining</title>
            <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had corneal staining graded 2 or higher at the 1-week visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings - Corneal Staining</title>
        <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had corneal staining graded 2 or higher at the 1-week visit.</description>
        <time_frame>after 1 month of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Slit Lamp Findings - Corneal Staining</title>
            <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had corneal staining graded 2 or higher at the 1-week visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings - Injection</title>
        <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had injection graded 2 or higher at the 1-week visit.</description>
        <time_frame>after 1 week of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Slit Lamp Findings - Injection</title>
            <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had injection graded 2 or higher at the 1-week visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings - Injection</title>
        <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had injection graded 2 or higher at the 1-week visit.</description>
        <time_frame>after 1 month of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Slit Lamp Findings - Injection</title>
            <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had injection graded 2 or higher at the 1-week visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings - Tarsal Abnormalities</title>
        <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had tarsal abnormalities graded 2 or higher at the 1-week visit.</description>
        <time_frame>after 1 week of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Slit Lamp Findings - Tarsal Abnormalities</title>
            <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had tarsal abnormalities graded 2 or higher at the 1-week visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings - Tarsal Abnormalities</title>
        <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had tarsal abnormalities graded 2 or higher at the 1-week visit.</description>
        <time_frame>after 1 month of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Slit Lamp Findings - Tarsal Abnormalities</title>
            <description>Investigators examined subjects using a slit lamp and the following scale:0=none, 1=trace, 2=mild, 3=moderate, 4= severe. This outcome measures the number of eyes that had tarsal abnormalities graded 2 or higher at the 1-week visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings - Infiltrates</title>
        <description>Investigators examined subjects using a slit lamp and recorded the presence or absence of infiltrates. This outcome measures the number of eyes that had infiltrates present at the 1-week visit.</description>
        <time_frame>after 1 week of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Slit Lamp Findings - Infiltrates</title>
            <description>Investigators examined subjects using a slit lamp and recorded the presence or absence of infiltrates. This outcome measures the number of eyes that had infiltrates present at the 1-week visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings - Infiltrates</title>
        <description>Investigators examined subjects using a slit lamp and recorded the presence or absence of infiltrates. This outcome measures the number of eyes that had infiltrates present at the 1-week visit.</description>
        <time_frame>after 1 month of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Slit Lamp Findings - Infiltrates</title>
            <description>Investigators examined subjects using a slit lamp and recorded the presence or absence of infiltrates. This outcome measures the number of eyes that had infiltrates present at the 1-week visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subject Reported Symptoms</title>
        <description>Number of eyes in which subjects reported lens-related symptoms after 1 week of lens wear.</description>
        <time_frame>after 1 week of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Subject Reported Symptoms</title>
            <description>Number of eyes in which subjects reported lens-related symptoms after 1 week of lens wear.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is that narafilcon B is not statistically different from etafilcon A.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0466</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subject Reported Symptoms</title>
        <description>Number of eyes in which subjects reported lens-related symptoms after 1 month of lens wear.</description>
        <time_frame>after 1 month of lens wear</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Subject Reported Symptoms</title>
            <description>Number of eyes in which subjects reported lens-related symptoms after 1 month of lens wear.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is that narafilcon B is not statistically different from etafilcon A.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1069</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity (VA)</title>
        <description>Investigators assessed visual acuity per eye using a Snellen visual acuity chart. This outcome measures the number of eyes, wearing vision correction, that measured visual acuity worse than 20/30 at the 1-week visit.</description>
        <time_frame>after 1 week</time_frame>
        <safety_issue>No</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Visual Acuity (VA)</title>
            <description>Investigators assessed visual acuity per eye using a Snellen visual acuity chart. This outcome measures the number of eyes, wearing vision correction, that measured visual acuity worse than 20/30 at the 1-week visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is that narafilcon B is not statistically different from etafilcon A.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4605</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity (VA)</title>
        <description>Investigators assessed visual acuity per eye using a Snellen visual acuity chart. This outcome measures the number of eyes, wearing vision correction, that measured visual acuity worse than 20/30 at the 1-month visit.</description>
        <time_frame>after 1 month</time_frame>
        <safety_issue>No</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Visual Acuity (VA)</title>
            <description>Investigators assessed visual acuity per eye using a Snellen visual acuity chart. This outcome measures the number of eyes, wearing vision correction, that measured visual acuity worse than 20/30 at the 1-month visit.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is that narafilcon B is not statistically different from etafilcon A.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5774</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Wear Time</title>
        <time_frame>after 1 week of lens wear</time_frame>
        <safety_issue>No</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Average Wear Time</title>
            <units>hours per day</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13.9" spread="1.91"/>
                  <measurement group_id="O2" value="13.7" spread="2.41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is that narafilcon B will not be statistically different from etafilcon A.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.6403</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Wear Time</title>
        <time_frame>after 1 month of lens wear</time_frame>
        <safety_issue>No</safety_issue>
        <population>This analysis includes all participants that completed the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>single use, daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A</title>
            <description>contact lens worn as single use, daily wear</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Average Wear Time</title>
            <units>hours per day</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13.6" spread="2.33"/>
                  <measurement group_id="O2" value="13.8" spread="2.24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is that narafilcon B is not statistically different from etafilcon A.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.7217</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Narafilcon B</title>
          <description>single use, daily wear contact lens</description>
        </group>
        <group group_id="E2">
          <title>Etafilcon A</title>
          <description>contact lens worn as single use, daily wear</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Buch/Principal Research Optometrist</name_or_title>
      <organization>Vistakon</organization>
      <phone>904-443-1707</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
